2025 Schedule

November 13 – 14, 2025 • Ritz-Carlton Laguna Niguel,

Dana Point, CA

Schedule

PART I

Moving Personalized Medicine Forward: Advancements and Directions for the Future

7:30 a.m.
Registration and Breakfast
8:30 a.m.
Opening Remarks

SPEAKER | Daryl Pritchard, Ph.D., President, Personalized Medicine Coalition

8:45 a.m.
The Past, Present, and Future of Innovation in Personalized Medicine: A Fireside Chat with Peter Marks

MODERATOR | Lauren Silvis, J.D., Senior Vice President, External Affairs, Tempus

KEYNOTE SPEAKER | Peter Marks, M.D., Ph.D., Former Director, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration

9:15 a.m.
Beyond Gene Testing: Next Generation Personalized Medicine Diagnostic Technologies in Clinical Practice (Proteomics, Metagenomics, ctDNA, and Digital Tools)

This session explores the cutting edge of personalized medicine beyond traditional gene testing, highlighting the clinical integration of next-generation diagnostic technologies. Experts will discuss the promise and practical application of proteomics, metagenomics, circulating tumor DNA (ctDNA), and digital diagnostic tools in delivering more precise, timely, and individualized care.

MODERATOR | Yuri Fesko, M.D., Senior Vice President & Chief Medical Officer, Quest Diagnostics

PANELIST | Esther Abels, Founder & CEO, SolarisRTC

PANELIST | Lourdes Barrera, Executive Director, Global Medical Affairs Oncology, Precision Medicine, Merck

PANELIST | David Kurtz, M.D., Ph.D., Co-Founder, Chief Medical Officer, Head of Research Foresight Diagnostics

PANELIST | Ofer Sharon, M.D., CEO, OncoHost

10:00 a.m.
Networking Break
10:45 a.m.
The Business of Personalized Medicine: Developing Viable Commercial Strategies for Personalized Medicine Companies

Industry innovation in diagnostic technologies and targeted treatment strategies drives progress in personalized medicine. But the path to market is fraught with obstacles. Pioneering investors and executives reflect on how to deal with challenges and uncertainty in an increasingly variable development and market environment.

MODERATOR | Kristin Ciriello Pothier, Life Sciences Sector Leader, Global Deal
Advisory and Strategy Leader, Healthcare and Life Sciences KPMG LLP

PANELIST | Namandjė Bumpus, Ph.D., Strategic Advisor, Healthcare Policies and Scientific Strategy, Avalere Health, Former U.S. FDA Principal Deputy Commissioner

PANELIST | Andy Moye, Ph.D., Senior Vice President and General Manager of Data Products, Tempus

PANELIST | Michael J. Pellini, M.D., Managing Partner, Section 32

 

 

11:30 a.m.
Blood-Based Diagnostic Strategies: Business and Clinical Approaches for the Future of Precision Oncology

MODERATOR | Invited 

KEYNOTE SPEAKER | Helmy Eltoukhy, Ph.D., Co-Chief Executive Officer & Chairman of the Board, Guardant Health

KEYNOTE SPEAKER | AmirAli Talasaz, PhD., Co-Chief Executive Officer & Director, Guardant Health

12:00 p.m.
Lunch Break and Sponsored Lunch Breakout Sessions
1:00 p.m.
The Future of Cancer if We Deliver on the Promise of Emerging Early Detection Technologies

By detecting molecular cancer signals in blood samples of seemingly healthy patients, a new generation of early cancer detection tests promises to put more patients on the path to personalized cancer treatment, sooner, when cancer may be more effectively treated. What might this mean for the future of cancer care? Leading voices discuss.

MODERATOR | Omar Perez, Ph.D., U.S. Head of Medical Diagnostics, AstraZeneca

PANELIST | Tomasz Beer, M.D., Chief Medical Officer, Multi-Cancer Early Detection, Exact Sciences

PANELIST | Ora K. Gordon, M.D., Executive Director of Cancer Services, St. John Cancer Institute & Disney Family Cancer Center, Providence Health

PANELIST | Eric Klein, M.D., Vice President, Distinguished Scientist, GRAIL

PANELIST | Dawn Mattoon, Ph.D., Chief Executive Officer, Mercy BioAnaytics, Inc.

 

1:45 p.m.
Personalized Medicine and the Pharmaceutical Industry: A Keynote Interview

MODERATOR | Invited 

KEYNOTE SPEAKER | Invited 

2:15 p.m.
Artificial Intelligence Driven Platforms Driving Biomarker and Treatment Development

Machine Learning and Artificial intelligence technologies can drive biomarker discovery and validation and more readily explore divergent effects of preventive and treatment interventions across extensive data sets. What might this mean for the future of personalized medicine and what is being done to realize that future?

MODERATOR | Douglas Clark, M.D., Chief Pathologist, Life Sciences and Diagnostics Markets Group, Agilent Technologies

PANELIST | Michael Montalto, Ph.D., Vice President, Precision Medicine Global

PANELIST | Invited

PANELIST | Invited

PANELIST | Invited

3:00 p.m.
Networking Break
3:30 p.m.
Presentation of the 20th Annual Award for Leadership in Personalized Medicine

PRESENTER | William S. Dalton, M.D., Ph.D., Founder & Senior Advisor, Aster Insights and Emeritus Senior Member, H. Lee Moffitt Cancer Center and Research Institute

AWARDEE | George Poste, D.V.M., Ph.D., Regents’ Professor and Del E. Webb Chair in Health Innovation and Chief Scientist, Complex Adaptive Systems Initiative, Arizona State University

 

4:00 p.m.
Emerging Personalized Medicine Disciplines: Biomarker-driven treatment strategies in cardiovascular, neurodegenerative, and infectious diseases

MODERATOR | Dan Roden, M.D., Professor, Department of Medicine & Pharmacology, Senior Vice President, Personalized Medicine, and Professor Department of Biomedical Informatics, Vanderbilt University Medical Center

PANELIST | Doug Biehn, President & CEO, Octave Bioscience, Inc.

PANELIST | Damon Hostin, Global Lead, Market Access, Illumina

PANELIST | Brad Perkins, M.D., Chief Medical Officer, Karius Diagnostics

 

4:45 p.m.
Engaging with the Global Community is More Important than Ever: International Efforts in Personalized Medicine and Advanced Technologies

MODERATOR | David Morrow, Ph.D., Scientific Lead for Advanced Therapies, European Infrastructure for Translational Medicine (EATRIS)

PANELIST | Gabriele Allegri, Vice President, Global Commercial Precision Medicine, Johnson & Johnson Innovative Medicine

PANELIST | Ayah Ziyada, MSc. Ph.D. Candidate, Precision Medicine Program Manager, Center for Clinical Precision Medicine and Genomics, Hamad Medical Corporation, Qatar

PANELIST | Invited

5:30 p.m.
Welcome Reception

PART II

Implementing Personalized Medicine in a New Era

7:30 a.m.
Registration and Breakfast
8:30 a.m.
Opening Remarks

SPEAKER | Lincoln Nadauld, M.D., Ph.D., President & CEO, Culmination Bio

8:45 a.m.
Personalized Medicine Without Limits, Technological Breakthroughs Enabling Individualized Care

MODERATOR | Cynthia Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition

KEYNOTE SPEAKER | Invited

9:15 a.m.
Artificial Intelligence for Biomarker-Driven Clinical Decision Support and Implementation of Personalized Medicine

MODERATOR | Invited 

PANELIST | Thomas Brown, M.D., Chief Medical Officer, Sygnomics

PANELIST | Okan Ekinci, M.D., Chief Medical Information Officer & Global Head of Digital Technology, Roche Information Solutions, Roche Diagnostics

PANELIST | Apostolia Tsimberidou, M.D., Ph.D., Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

10:00 a.m.
Networking Break
10:30 a.m.
What is needed to Improve the Delivery of Personalized Medicine? A Strategic Roadmap for Implementing Precision Oncology

Our scientific understanding and technological development for personalized medicine is way ahead of the policies and practices needed to fully realize the field’s value. Clinical implementation of personalized medicine technologies is fraught with challenges. A community approach to developing and implementing strategies to more consistently and effectively deliver personalized medicine is gaining traction. But, much is still needed to be done. What is needed to improve access and implementation?

MODERATOR | Burns Blaxall, Ph.D., Senior Vice President, Precision Medicine, Aranscia

PANELIST | Suzzette Arnal, Ph.D., Senior Director, Precision Medicine, The U.S. Oncology Network

PANELIST | Jonathan Katchmore, Associate Vice President, Commercial Diagnostic Strategy, Eli Lilly and Company

PANELIST | Prajit Pillai, Ph.D., Co-Founder and Head of Business Strategy & Technology Development, Precision Medicine Diagnostic Partners

PANELIST | Invited

LEARN MORE
11:15 a.m.
Recognizing the Clinical Utility of Personalized Medicine: Market Access Perspectives related to Value, Coverage, and Reimbursement

MODERATOR | Suzanne Belinson, Ph.D., Vice President of Commercial Markets, Tempus

PANELIST | Lon Castle, M.D., Chief Medical Officer, Precision Medicine, eviCore healthcare

PANELIST | Cate Lockhart, Pharm.D., Ph.D., Chief Science Officer, Academy of Managed Care Pharmacy

PANELIST | Kathryn Phillips, Ph.D., Founding Director, Center for Translational & Policy Research on Personalized Medicine (TRANSPERS), University of California San Francisco

 

12:00 p.m.
Closing Remarks

SPEAKER | Brian Munroe, Vice President, Government Affairs, Bausch Health Companies

12:05 p.m.
Lunch Buffet